Hepatitis B virus-related hepatocellular carcinogenesis and its prevention

Intervirology

Volumn 48, Issue 1, 2005, Pages 29-38

  Ikeda, Kenji ^a   Arase, Yasuji ^b   Kobayashi, Masahiro ^b   Someya, Takashi ^b   Hosaka, Tetsuya ^b   Saitoh, Satoshi ^b   Sezaki, Hitomi ^b   Akuta, Norio ^b   Suzuki, Fumitaka ^b   Suzuki, Yoshiyuki ^b   Kumada, Hiromitsu ^b  

^a TORANOMON HOSPITAL   (Japan)

^b NONE

Author keywords

Cancer prevention; Carcinogenesis; DNA; Hepatitis B virus; Hepatocellular carcinoma; Interferon; Liver cirrhosis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; VIRUS DNA;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA DETERMINATION; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEQUENTIAL ANALYSIS; VIRUS LOAD; VIRUS VIRULENCE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA, VIRAL; EARLY DIAGNOSIS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 20244368049     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082092     Document Type: Review

References (33)

1. Parkin DM, Stjernsward J, Muir CS: Estimates of worldwide frequency of twelve major cancere. Bull Wld Hlth Org 1984;62:163-182.
2. Okuda K: Early recognition of hepatocellular carcinoma. Hepatology 1986;6:729-738.
3. The Liver Cancer Study Group of Japan: Primary liver cancer in Japan: Clinicopathological features and results of surgical treatment. Ann Surg 1990;211:277-287.
4. Prince AM, Szmuness W, Michon J, Desmaille J, Diebolt G, Linhard J, Quenum C, Sankale M: A case-control study of the association between primary liver cancer and hepatitis B infection in Senegal. Int J Cancer 1975;16:376-383.
5. Ohnishi K, Iida S, Iwama S, Goto N, Nomura F, Takashi M, Mishima A, Kono K, Kimura K, Musha H, Kotota K, Okuda K: The effect of chronic habitual alcohols intake on the development of liver cirrhosis and hepatocellular carcinoma. Relation to hepatitis B surface antigen carriage. Cancer 1982;49:672-677.
6. Lam KC, Yu MC, Leung JWC, Henderson BE: Hepatitis B virus and cigarette smoking: Risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res 1982;42:5246-5248.
7. Shafritz D, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 1981;305:1067-1073.
8. Brechot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, Bismuth H, Trepo C, Benhamou JP, Wands J: Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1981;312:270-276.
9. Nagaya T, Nakamura T, Tokino T, Tsurimoto T, Imai M, Mayumi T, Kamino K, Yamamura K, Matsubara K: The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1987;1:773-782.
10. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 cases with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
11. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
12. Weimar W, Heijtink RA, Kate FJ, et al: Double blind study of leukocyte interferon administration in chronic HBsAg positive hepatitis. Lancet 1980;i:336-338.
13. Alexander GJ, FagenEA, Guarner P, et al: A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therapy in chronic hepatitis B virus infection. J Hepatol 1986;3(suppl 2):S183-S188.
14. Dusheiko GM, Paterson AC, Pitcher L, et al: Recombinant leukocyte interferon treatment of chronic hepatitis B. J Hepatol 1986;3(suppl 2):S199-S207.
15. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-748.
16. Lok AS, Weller IV, Karrayanis P, et al: Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984;4:45-49.
17. Koreman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH: Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634.
18. Wong JB, Koff RS, Tine F, Pauker SG: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-675.
19. Dusheiko GM, Roberts JA: Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995;22:1863-1873.
20. Oon CL: Long-term survival following treatment of hepatocellular carcinoma in Singapore: Evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992;31(suppl):S137-S142.
21. Mazzella G, Accogli E, Sottili S, et al: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
22. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis. Hepatology 1997;26:1338-1342.
23. Ikeda K, Saitoh S, Suzuki Y, et al: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. Cancer 1998;82:827-835.
24. International Interferon-alpha Hepatocellular Carcinoma Study Group: Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-1539
25. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-975.
26. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S: Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 1999;2:310-314.
27. SAS Institute Inc: SAS/STAT User's Guide, Release 6.03 Edition. Cary, 1988.
28. Ikeda K, Arase Y, Kobayashi M, Someya T, Saitoh S, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H: Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. Intervirology, 2003;46:96-104.
29. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, Kumada H: Relationship of hepatocellular carcinogenesis with precore mutant virus and serum hepatitis B virus DNA concentration. A longitudinal analysis of patients with cirrhosis. Hepatol Res 1998;10:142-155.
30. Roeckelein G, Hecken-Emmel M: Risk factors of hepatocellular carcinoma in Germany: Hepatitis B or liver cirrhosis? Hepato-gastroenterology 1988;35:151-157.
31. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457-481.
32. SPSS Inc: SPSS for Windows version 11.0 manual. SPSS, Chicago, 2001.
33. Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Kumada H: Significance of hepatitis-B virus DNA clearance and its early prediction in hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: A long-term follow-up of a pilot study. J Gastroenterol Hepatol 2004; in press.